The potential role of gene therapy in the treatment of bladder cancer

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 103-113

  Hsieh, Jer Tsong ^a   Dinney, Colin P N ^b   Chung, Leland W K ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

BLADDER CANCER; CARCINOGENESIS; CLINICAL RESEARCH; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOGENETICS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0033980226     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70238-X     Document Type: Article

References (83)

1. I. Aksentijevich C.O. Cardarelli I. Pastan Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity Clin Cancer Res 86 1996 973
2. J.A. Allay L.L. Dumenco O.N. Koc Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells Blood 85 1995 3342
3. S. Baron F. Dianzani The interferons: A biological system with therapeutic potential in viral infections Antiviral Res 24 1994 97
4. + tumor cells are potent vaccines for stimulating tumor rejection in tumor bearing mice J Exp Med 181 1995 619
5. C. Bass G. Cabrerra A. Elgavish Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo Cancer Gene Ther 2 1995 97
6. J.M. Bergelson G. Cunningham Drouguett E.A. Kurt-Jones Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 Science 275 1997 1320
7. D. Bielenberg P. Perrotte J.W. Slaton Systemic administration of interferon-alpha (IFN-α) decreases expression of metalloproteinase type 9 (MMP-9), angiogenesis and growth of human transitional cell carcinoma (TCC) growing in athymic nude mice J Urol 159 1998 1063A
8. J.R. Bischoff D.H. Kirn A. Williams An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373
9. J. Brzoska H.J. Obert Immunomodulating effects of interferons: Conclusions for therapy S. Gorss H. Jablonska Genital Papillomavirus Infections 1990 Springer-Verlag Berlin 379
10. P. Cairns C.S. Liu D. Sidransky Molecular biology of bladder cancer D. Raghavan H.I. Scher S.A. Laibel Principles of Genitourinary Oncology 1997 Lippincott-Raven New York 223
11. L. Chen D. Chen E. Block Eradication of murine bladder carcinoma by intratumor injection of a bistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by IL-12 p40 subunit homodimer J Immunol 159 1997 351
12. L.W.K. Chung Implication of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation Semin Cancer Biol 4 1993 183
13. K.M. Dameron O.V. Volpert M.A. Tainsky The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin Cold Spring Harb Symp Quant Biol 59 1994 483
14. C. Defer M.T. Belin M.L. Caillet-Boudin Human adenovirus–host cel interactions: Comparative study with members of subgroup B and C J Virol 64 1990 3661
15. J.H. Doroshow M.Z. Metz L. Matsumoto Transduction of NIH3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad range multidrug resistance Cancer Res 55 1995 4073
16. G. Dranoff E. Jaffee A. Lazenby Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage-colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 90 1993 3539
17. S. Einhorn D. Grander Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 16 1996 275
18. W.S. El-Diery T. Tokino V.E. Velculescu WAF 1, a potential mediator of p53 tumor suppression Cell 75 1993 817
19. D. Esrig D. Elmajian S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259
20. M. Feng G. Cabrera J. DeShane Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti- ras ribozyme Cancer Res 55 1995 2024
21. G. Fierlbeck A. Ulmer T. Schreiner Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma J Interferon Cytokine Res 16 1996 777
22. S. Freeman C. Abbound K. Whartenby The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 53 1993 5274
23. H. Fujii M. Inobe F. Kimura Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice Int J Cancer 66 1996 219
24. K. Fujimoto Y. Yamada E. Okajima Frequent association of p53 gene mutation in invasive bladder cancer Cancer Res 52 1992 1393
25. M.E. Gleave J.T. Hsieh C. Gao Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts Cancer Res 51 1991 3753
26. H. Golomb E. Ellis Treatment options for hairy-cell leukemia Semin Oncol 18 1991 7
27. L.G. Gomella M.J. Mastrangelo L.C. Eisenlohr Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer Proc Am Assoc Cancer Res 38 1997 9
28. A. Gorlach P. Herter H. Hentschel Effects of nIFN-β and rIFN-γ on growth and morphology of two human melanoma cell lines: Comparison between two- and three-dimensional culture Int J Cancer 56 1994 249
29. G.D. Grossfeld D.A. Ginsberg J.P. Stein Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression J Natl Cancer Inst 89 1997 219
30. H.B. Grossman Surgical staging and surgery for superficial bladder cancer D. Raghavan H.I. Scher S.A. Laibel Principles of Genitourinary Oncology 1997 Lippincott-Raven New York 269
31. A. Grunhaus M.S. Horwitz Adenovirus as cloning vector Semin Virol 3 1992 237
32. E. Guinan J. Gribben V. Boussiotis Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity Blood 84 1994 3261
33. J.U. Gutterman Cytokine therapeutics: Lessons from interferon-β Proc Natl Acad Sci USA 91 1994 1198
34. M.C. Hall Y. Li B. Ely Function role of p21 (WAF-1/CIP-1) in human bladder cancer progression and potential gene therapy application J Urol 1999 in press
35. K.M. Hapke A.P.A. Stegmann B.S. Mitchell Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity Cancer Res 56 1996 2343
36. J.W. Harper G.R. Adami N. Wei The p21 Cdk-interacting protein CIP 1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75 1993 805
37. M.P. Harris S. Sutjipto F.N. Wills Adenovirus mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein Cancer Gene Ther 3 1996 121
38. Y. Hashimoto K. Kohri H. Akita Efficient transfer of genes into senescent cels by adenovirus vectors via highly expressed αvβ5 integrin Biochem Biophy Res Commun 240 1997 88
39. S. Hemmi A. Geersten I. Mezzacasa The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures Hum Gene Ther 9 1998 2363
40. P.J. Hertzog S.Y. Hwang I. Kola Role of interferons in the regulation of cell proliferation, differentiation, and development Mol Reprod Dev 39 1994 226
41. A. Keyhani B. Liu C.P.N. Dinney p53 adenovirus-mediated gene transfer in bladder cancer Clin Res 40 1999 3477
42. A. Kieser H.A. Weich G. Brandner Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression Oncogene 9 1994 963
43. D. Kleinerman P. Troncoso T. Brooks The expression of an epithelial cell adhesion molecule (C-CAM) in human prostate development and in prostate carcinoma: Implication as a tumor suppressor Cancer Res 55 1995 1215
44. S.E. Krown Interferons in malignancy: Biological products or biological response modifiers? J Natl Cancer Inst 80 1988 306
45. Y. Li R.C. Pong M.C. Hall Loss of adenoviral receptor expression in human bladder cancer cells—a potential impact on the efficacy of gene therapy Cancer Res 59 1999 325
46. T. Licht I. Aksentijevich M.M. Gottesman Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells Blood 86 1995 11
47. P.J. Loehrer P.H.M. De Mulder Management of metastatic bladder cancer D. Raghavan H.I. Scher S.A. Laibel Principles of Genitourinary Onclogy 1997 Lippincott-Raven New York 299
48. C. Logothetis D. Swanson R. Amato Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective, comparative trial of pre- and post-operative chemotherapy for invasive bladder carcinoma J Urol 155 1996 1241
49. C.J. Logothetis H. Xu J.Y. Ro Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer J Natl Cancer Inst 84 1992 1256
50. A. Lokshin J.E. Mayotte M.L. Levitt Mechanism of interferon-beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines J Natl Cancer Inst 87 1995 206
51. G. Maass W. Schmidt M. Berger Priming of tumor specific T cells in the draining lymph nodes after immunization with interleukin 2 secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination Proc Natl Acad Sci USA 92 1995 5540
52. S.B. Malkowicz J.E. Tomaszewski A.J. Linnenbach Novel p21WAF1/CIP1 mutation in superficial and invasive transitional cell carcinoma Oncogene 13 1996 1831
53. R.C. Miller D.J. Buchsbaum P.N. Reynolds Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via epidermal growth factor receptor achieves fiber receptor-independent gene transfer Cancer Res 58 1998 5738
54. D. Mukhopadhyay L. Tsiokas V.P. Sukhatme Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression Cancer Res 55 1995 6161
55. L. Pagliaro P. Perrotte M. Wood Safety and distribution of in vivo adenovirus-p53 (Ad-p53) after intravesical administration J Urol 159 1998 1064A
56. P. Perrotte K. Inoue J.W. Slaton Intralesional gene transfer inhibits the growth of human transitional cell carcinoma (TCC) growing in athymic nude mice by inhibition of angiogenesis and activation of macrophages J Urol 161 1999 432
57. K.G. Rendahl S.E. Leff G.R. Otten Regulation of gene expression in vivo following transduction by two separate rAAV vectors Nat Biotechnol 16 1998 757
58. P.D. Robbins S.C. Ghivizzani Viral vectors for gene therapy Pharmacol Ther 80 1998 35
59. I.B. Runnebaum Basics of cancer gene therapy Anticancer Res 17 1997 2887
60. P. Salmon J.Y. le Cotonnec A. Galazka Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers J Interferon Cytokine Res 16 1996 759
61. P. Schwarzenberger S. Spence N. Lohrey Gene transfer of multidrug resistance into a factor-dependent human hematopoietic cell line: In vivo model for genetically transferred chemoprotection Blood 87 1996 2273
62. J.D. Seigne S.X. Hu K.T. Kong Rationale and development of retinoblastoma (RB) tumor suppressor gene therapy for bladder cancer J Urol 155 1996 320A
63. C.J. Sherr Cancer cell cycles Science 274 1996 1672
64. T. Shirakawa S.C. Ko T.A. Gardner In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy Cancer Gene Ther 5 1998 274
65. D. Sidransky A. Von Eschenbach Y.C. Tsai Identification of p53 gene mutations in bladder cancers and urine samples Science 252 1991 706
66. H.T. Spencer S.E.H. Sleep J.E. Rehg A gene transfer strategy for making bone marrow cells resistant to trimetrexate Blood 87 1996 2579
67. J.P. Stein D.A. Ginsberg G.D. Grossfeld The significance of p21 WAF1/CIP1 expression and tumor progression in bladder cancer J Urol 157 1997 161A
68. J.P. Stein G.D. Grossfeld D.A. Ginsberg Prognostic markers in bladder cancer: A contemporary review of the literature J Urol 160 1998 645
69. S.C. Stevenson M. Rollence B. White Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain J Virol 69 1995 2850
70. L. Stratford-Perricaudet M. Perricaudet Gene transfer into animals: The promise of adenovirus Human Gene Transfer 1991 Colloque INSERM, John Libbey Eurotaxt Ltd New York 51
71. M.A. Sutton S.A. Berkman S. Chen Adenovirus-mediated suicide gene therapy for experimental bladder cancer Urology 49 1997 173
72. M. Talpaz M. Rosenbloom R. Kurzrock Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia—a pilot study Am J Hematol 24 1997 341
73. B.J. Thasher D. Crawford Current management of invasive and metastatic transitional cell carcinoma J Urol 149 1993 957
74. H. Thomas F.R. Balkwill Effects of interferons and other cytokines on tumors in animals: A review Pharmacol Ther 52 1991 307
75. R.P. Tomoko R. Xu L. Philipson HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses Proc Natl Acad Sci USA 94 1997 3352
76. Q. Trinh E. Austin D. Murray Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line Cancer Res 55 1995 4808
77. G.P. Tuszynski R.F. Nicosia The role of thrombospondin-1 in tumor progression and angiogenesis Bioessays 18 1996 71
78. T. Ueba T. Nosaka J.A. Takahashi Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells Proc Natl Acad Sci USA 91 1994 9009
79. O.V. Volpert V. Stellmach N. Bouck The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression Breast Cancer Res Treat 36 1995 119
80. M. Wei T. Tamiya M. Chase Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene Hum Gene Ther 5 1994 969
81. P.E. Werthman K.E. Drazan J.T. Rosenthal Adenoviral- p53 gene transfer to orthotopic and peritoneal murine bladder cancer J Urol 155 1996 753
82. Y. Yang F.A. Nunes K. Berencsi Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc Natl Acad Sci USA 91 1994 4407
83. W. Zhang L. Grosso C.D. McClain p53-independent induction of WAF 1/CIP 1 in human leukemia cells is correlated with gross arrest accompanying monocyte/macrophage differentiation Cancer Res 55 1995 668